Российский междисциплинарный консенсус по диагностике и лечению спондилоартритов при воспалительных заболеваниях кишечника

Лукина Г.В., Князев О.В., Белоусова Е.А., Абдулганиева Д.И., Александрова Е.Н., Бакулин И.Г., Барышева О.Ю., Борисова М.А., Выкова Б.А., Годзенко А.А., Губонина И.В., Дубинина Т.В., Жигалова Т.Н., Жиляев Е.В., Каграманова А.В., Коротаева Т.В., Кузин А.В., Ливзан М.А., Лила А.М., Мазуров В.И., Насонов Е.Л., Новиков А.А., Осипенко М.Ф., Парфенов А.И., Тарасова Л.В., Хлынова О.В., Шапина М.В., Щукина О.Б., Эрдес Ш.Ф., Яковлев А.А. Российский междисциплинарный консенсус по диагностике и лечению спондилоартритов при воспалительных заболеваниях кишечника. Терапевтический архив. 2025;97(2):198–213. DOI: 10.26442/00403660.2025.02.203117

© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.

________________________________________________

Lukina GV, Knyazev OV, Belousova EA, Abdulganieva DI, Aleksandrova EN, Bakulin IG, Barysheva OIu, Borisova MА, Vykova BА, Godzenko AА, Gubonina IV, Dubinina TV, Zhigalova TN, Zhilyaev EV, Kagramanova AV, Korotaeva TV, Kuzin AV, Livzan MA, Lila AM, Mazurov VI, Nasonov EL, Novikov AA, Osipenko MF, Parfenov AI, Tarasova LV, Khlynova OV, Shapina MV, Shchukina OB, Erdes ShF, Iakovlev AA. Russian Cross-disciplinary Consensus on the diagnosis and treatment of spondyloarthritis associated with inflammatory bowel diseases. Terapevticheskii Arkhiv (Ter. Arkh.). 2025;97(2):198–213. DOI: 10.26442/00403660.2025.02.203117

Читать PDF

Аннотация

Российский междисциплинарный консенсус по диагностике и лечению спондилоартритов (СпА) при воспалительных заболеваниях кишечника (ВЗК) подготовлен по инициативе ГБУЗ «МКНЦ им. А.С. Логинова» по Дельфийской системе. Его целью явилась консолидация мнений отечественных специалистов по наиболее актуальным вопросам диагностики и лечения сочетанных иммуновоспалительных заболеваний (СпА и ВЗК). Междисциплинарный подход обеспечен участием ведущих гастроэнтерологов и ревматологов. Рабочей группой проанализированы отечественные и иностранные публикации, посвященные проблеме курации пациентов со СпА и ВЗК. Сформулировано 17 положений и 2 алгоритма лечения. Положения 1–3 отражают основополагающие принципы ведéния пациентов со СпА и ВЗК. Далее изложены принципы ранней диагностики СпА и ВЗК, в том числе и диагностики осложнений терапии. Одиннадцать положений посвящены современным методам лечения пациентов, на основании которых разработаны 2 алгоритма лечения. Положения консенсуса были представлены на рассмотрение экспертного совета, внесены правки, после чего состоялось онлайн-голосование. В данной работе представлены актуальные рекомендации по ведéнию, диагностике и лечению пациентов со СпА и ВЗК.

Ключевые слова: консенсус, воспалительные заболевания кишечника, спондилоартрит, лечение, диагностика

________________________________________________

The Russian Cross-disciplinary Consensus on the diagnositic and treatment of spondyloarthritis (SpA) in inflammatory bowel diseases (IBD) was prepared on the initiative of the Loginov Moscow Clinical Scientific Center, using the Delphic system. Its purpose was to consolidate the opinions of experts on the most actual issues of diagnosis and treatment of concomitant immuno-inflammatory diseases (SpA and IBD). An interdisciplinary approach is provided by the participation of leading gastroenterologists and rheumatologists. The working group analyzed domestic and foreign publications on the problem of curation of patients with SpA and IBD. There have been 17 statements and 2 treatment algorithms formulated. Statements 1–3 reflect the fundamental principles of management of patients with SpA and IBD. The principles of early diagnosis of SpA and IBD, including the diagnosis of complications of therapy, are described below. Eleven statements are devoted to current methods of treatment, on the basis of which 2 treatment algorithms have been developed. The statements of the Consensus were submitted to the Expert Council for consideration, edits were made, after which an online vote took place. This paper presents current recommendations for the management, diagnosis and treatment of patients with SpA and IBD.

Keywords: consensus, inflammatory bowel diseases, spondyloartritis, treatment, diagnostics

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Насонов Е.Л., Абдулганиева Д.И., Файрушина И.Ф. Место тофацитиниба в лечении воспалительных заболеваний кишечника. Терапевтический архив. 2019;91(2):101-8 [Nasonov EL, Abdulganieva DI, Fairushina IF. The use of Tofacitinib in the treatment of inflammatory bowel disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(2):101-8 (in Russian)]. DOI:10.26442/00403660.2019.02.000155
2. Harbord M, Annese V, Vavricka SR, et al.; European Crohn’s and Colitis Organisation. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239-54. DOI:10.1093/ecco-jcc/jjv213
3. Hedin CRH, Vavricka SR, Stagg AJ, et al. The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis. 2019;13(5):541-54. DOI:10.1093/ecco-jcc/jjy191
4. Gutiérrez Casbas A, Rodríguez-Lago I, Marín-Jiménez I, et al.; EISER Study Group. DOP60 Prevalence of undiagnosed inflammatory Bowel Disease in patients with spondyloarthritis: EISER Study. J Crohn's and Colitis. 2024;18(Suppl. 1):i182-4. DOI:10.1093/ecco-jcc/jjad212.0100
5. Atzeni F, Defendenti C, Ditto MC, et al. Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):20-3. DOI:10.1016/j.autrev.2013.06.006
6. Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г., и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 [Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Rheumatology Science and Practice. 2015;53(6):657-60 (in Russian)]. DOI:10.14412/1995-4484-2015-657-660
7. Эрдес Ш.Ф. Развитие концепции спондилоартритов. Научно-практическая ревматология. 2014;52(5):474-6 [Erdes ShF. Spondyloarthritis: Evolution of a concept. Rheumatology Science and Practice. 2014;52(5):574-6 (in Russian)]. DOI:10.14412/1995-4484-2014-574-576
8. Эрдес Ш.Ф., Ребров А.П., Дубинина Т.В., и др. Спондилоартриты: современная терминология и определения. Терапевтический архив. 2019;91(5):84-8 [Erdes ShF, Rebrov AP, Dubinina TV, et al. Spondyloarthritis: Modern terminology and definitions. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(5):84-8 (in Russian)]. DOI:10.26442/00403660.2019.05.000208
9. Эрдес Ш.Ф. Анкилозирующий спондилит. В кн.: Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2020 [Erdes ShF. Ankiloziruiushchii spondilit. V kn.: Rossiiskie klinicheskie rekomendatsii. Revmatologiia. Pod red. EL Nasonova. Moscow: GEOTAR-Media, 2020 (in Russian)].
10. Poddubnyy D, van Tubergen A, Landewé R, et al.; Assessment of SpondyloArthritis international Society (ASAS). Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Ann Rheum Dis. 2015;74(8):1483-7. DOI:10.1136/annrheumdis-2014-207151
11. Годзенко А.А. Дифференциальная диагностика суставного синдрома. В кн.: Ревматология. Клинические лекции. Под ред. В.В. Бадокина. М.: Литтера, 2014 [Godzenko AA. Differentsial'naia diagnostika sustavnogo sindroma. V kn.: Revmatologiia. Klinicheskie lektsii. Pod red. VV Badokina. Moscow: Littera, 2014 (in Russian)].
12. Коротаева Т.В., Корсакова Ю.Л. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2018;56(1):60-9 [Korotaev TV, Korsakova YuL. Psoriatic arthritis: Classification, clinical presentation, diagnosis, treatment. Rheumatology Science and Practice. 2018;56(1):60-9 (in Russian)]. DOI:10.14412/1995-4484-2018-60-69
13. Rudwaleit M, Jurik A, Hermann K, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: A consensual approach by the ASAS/OMERACT MRI Group. Ann Rheum Dis. 2009;68(10):1520-7. DOI:10.1136/ard.2009.110767
14. Lambert R, Bakker P, van der Heijde D, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: Update by the ASAS MRI Working Group. Ann Rheum Dis. 2016;75(11):1958-63. DOI:10.1136/annrheumdis-2015-208642
15. Бочкова А.Г., Левшакова А.В. Краткое методическое руководство по обследованию больных спондилоартритами. М. 2012 [Bochkova AG, Levshakova AV. Kratkoe metodicheskoe rukovodstvo po obsledovaniiu bol'nykh spondiloartritami. Moscow. 2012 (in Russian)].
16. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65-73. DOI:10.1136/annrheumdis-2013-203582
17. Маев И.В., Бакулин И.Г., Скалинская М.И., Сказываева Е.В. Воспалительные заболевания кишечника: трансформация представлений. Терапевтический архив. 2023;95(12):1064-74 [Maev IV, Bakulin IG, Skalinskaya MI, Skazyvaeva EV. Inflammatory bowel diseases: Transformation of representations. A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(12):1064-74 (in Russian)]. DOI:10.26442/00403660.2023.12.202507
18. Linstone H, Turoff M. The Delphi method: Techniques and applications. Available at: https://web.archive.org/web/20080520015240/http:/is.njit.edu/pubs/delphibook/ Accessed: 22.01.2024.
19. Tavassoli S, Shahabinasab I, Norouzi A, et al. From bowel inflammation to the bone and joints: Musculoskeletal examination in inflammatory bowel disease (IBD). BMC Musculoskelet Disord. 2021;22(1):1019. DOI:10.1186/s12891-021-04903-4
20. Никитин А.В., Волынец Г.В., Скворцова Т.А., Капранова М.С. Внекишечные проявления воспалительных заболеваний кишечника. Доказательная гастроэнтерология. 2023;12(1):93-8 [Nikitin AV, Volynets GV, Skvortsova TA, Kapranova MS. Extraintestinal manifestations of inflammatory bowel disease. Russian Journal of Evidence-Based Gastroenterology. 2023;12(1):93-8 (in Russian)]. DOI:10.17116/dokgastro20231201193
21. Кузин А.В. Поражение суставов и позвоночника у больных с воспалительными заболеваниями кишечника. Современная ревматология. 2016;10(2):78-82 [Kuzin AV. Injury to the joint and spinal column in patients with inflammatory bowel diseases. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(2):78-82 (in Russian)]. DOI:10.14412/1996-7012-2016-2-78-82
22. Бакулин И.Г., Скалинская М.И., Сказываева Е.В., и др. Внекишечные проявления воспалительных заболеваний кишечника: современная концепция и вклад в представление о заболевании. Терапия. 2022;8(1):71-93 [Bakulin IG, Skalinskaya MI, Skazyvaeva EV, et al. Extraintestinal manifestations of inflammatory bowel diseases: Modern conception and contribution to the disease insight. Therapy. 2022;8(1):71-93 (in Russian)]. DOI:10.18565/therapy.2022.1.71-93
23. Эрдес Ш.Ф., Дубинина Т.В., Лапшина С.А., и др. Современные принципы медикаментозной терапии анкилозирующего спондилита. Практическая медицина. 2015;4-2(89):181-9 [Erdes ShPh, Dubinina TV, Lapshina SА, et al. Modern principles of medical treatment of ankylosing spondylitis. Practical Medicine. 2015;4-2(89):181-9 (in Russian)].
24. Эрдес Ш.Ф. Основные принципы терапии анкилозирующего спондилита (болезни Бехтерева). Научно-практическая ревматология. 2013;51(6):686-95 [Erdes ShF. The basic principles of treatment of ankylosing spondylitis (Bechterew's disease). Rheumatology Science and Practice. 2013;51(6):686-95 (in Russian)]. DOI:10.14412/1995-4484-2013-686-95
25. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. DOI:10.1136/annrheumdis-2016-210770
26. Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73(8):1455-61. DOI:10.1136/annrheumdis-2014-205178
27. Poddubnyy D, Protopopov M, Haibel H, et al. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: Results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis. 2016;75(12):2114-8. DOI:10.1136/annrheumdis-2016-209209
28. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65(4):442-52. DOI:10.1136/ard.2005.041137
29. Braun J, van den Berg R, Baraliakos X. Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896-904. DOI:10.1136/ard.2011.151027
30. Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А., и др. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Современная ревматология. 2018;12(3):4-18 [Abdulganieva DI, Bakulev AL, Belousova EA, et al. Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2018;12(3):4-18 (in Russian)]. DOI:10.14412/1996-7012-2018-3-4-18
31. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets Inflammatory Bowel Disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324-38. DOI:10.1038/ajg.2015.23358
32. Тurner D, Ricciuto A, Lewis A, et al.; International Organization for the Study of IBD. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83. DOI:10.1053/j.gastro.2020.12.031
33. Шелыгин Ю.А., Ивашкин В.Т., Ачкасов С.И., и др. Клинические рекомендации. Болезнь Крона (К50), взрослые. Колопроктология. 2023;22(3):10-49 [Shelygin YuA, Ivashkin VT, Achkasov SI, et al. Clinical guidelines. Crohn’s disease (К50), adults. Koloproktologia. 2023;22(3):10-49 (in Russian)]. DOI:10.33878/2073-7556-2023-22-3-10-49
34. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000;118(2):274-8. DOI:10.1016/s0016-5085(00)70209-5
35. Palm Ø, Moum B, Jahnsen J, Gran JT. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatol (Oxford). 2001;40(11):1256-61. DOI:10.1093/rheumatology/40.11.1256
36. Yüksel I, Ataseven H, Başar O, et al. Peripheral arthritis in the course of inflammatory bowel diseases. Dig Dis Sci. 2011;56(1):183-7. DOI:10.1007/s10620-010-1260-z
37. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol. 1988;83(7):703-9. PMID:3289378
38. Greenstein A, Janowitz H, Sachar D. Extra-intestinal complications of Crohn’s disease and ulcerative colitis. Medicine (Baltimore). 1976;55(5):401-12. DOI:10.1097/00005792-197609000-00004
39. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis. 2009;68(6):777-83. DOI:10.1136/ard.2009.108233
40. Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25-31. DOI:10.1136/ard.2010.133645
41. Salvarani C, Vlachonikolis IG, van der Heijde DM, et al.; European Collaborative IBD Study Group. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36(12):1307-13. DOI:10.1080/003655201317097173
42. Chen Y, Chen L, Xing C, et al. The risk of rheumatoid arthritis among patients with inflammatory bowel disease: A systematic review and meta-analysis. BMC Gastroenterol. 2020;20(1):192. DOI:10.1186/s12876-020-01339-3
43. Kärnsund S, Lo B, Bendtsen F, et al. Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J Gastroenterol. 2020;26(35):5362-74. DOI:10.3748/wjg.v26.i35.5362
44. Hidalgo DF, Boonpheng B, Phemister J, et al. Inflammatory bowel disease and risk of osteoporotic fractures: A meta-analysis. Cureus. 2019;11(9):e5810. DOI:10.7759/cureus.5810
45. Lo B, Holm JP, Vester-Andersen MK, et al. Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease: A Danish population-based inception cohort with 10 years of follow-up. J Crohns Colitis. 2020;14(7):904-14. DOI:10.1093/ecco-jcc/jjaa019
46. Komaki Y, Komaki F, Micic D, et al. Risk of fractures in inflammatory bowel diseases: A systematic review and meta-analysis. J Clin Gastroenterol. 2019;53(6):441-8. DOI:10.1097/MCG.0000000000001031
47. Szafors P, Che H, Barnetche T, et al. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int. 2018;29(11):2389-97. DOI:10.1007/s00198-018-4586-6
48. Шелыгин Ю.А., Ивашкин В.Т. , Белоусова Е.А., и др. Язвенный колит (К51), взрослые. Клинические рекомендации. Колопроктология. 2023;22(1):10-44 [Shelygin YuA, Ivashkin VT, Belousova EA, Ulcerative colitis (K51), adults. Clinical Guidelines. Koloproktologia. 2023;22(1):10-44 (in Russian)]. DOI:10.33878/2073-7556-2023-22-1-10-44
49. Дубинина Т.В., Гайдукова И.З., Годзенко А.А., и др. Рекомендации по оценке активности болезни и функционального состояния больных анкилозирующим спондилитом в клинической практике. Научно-практическая ревматология. 2017;55(4):344-50 [Dubinina TV, Gaidukova IZ, Godzenko AA, et al. Guidelines for the assessment of disease activity and functional status in patients with ankylosing spondylitis in clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):344-50 (in Russian)]. DOI:10.14412/1995-4484-2017-344-350
50. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl. 2):ii1-44. DOI:10.1136/ard.2008.104018
51. Van der Heijde D, Lie E, Kvien TK, et al.; Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811-8. DOI:10.1136/ard.2008.100826
52. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285-99. DOI:10.1002/acr.24025
53. Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20939410. DOI:10.1177/1759720X20939410
54. Wallace JL. Prostaglandin biology in inflammatory bowel disease. Gastroenterol Clin North Am. 2001;30(4):971-80. DOI:10.1016/s0889-8553(05)70223-5
55. Гайдукова И.З., Ребров А.П., Оттева Э.Н., и др. Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов). Научно-практическая ревматология. 2016;54(Прил. 1):67-74 [Gaidukova IZ, Rebrov AP, Otteva EN, et al. Use of nonsteroidal anti-inflammatory drugs for the treatment of axial spondyloarthritis, including ankylosing spondylitis, monitoring their efficacy and safety (draft guidelines of the Expert Spondyloarthritis Diagnosis and Treatment Group). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl. 1):67-74 (in Russian)]. DOI:10.14412/1995-4484-2016-1S-67-74
56. Cohen-Mekelburg S, Van T, Wallace B, et al. The association between nonsteroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: A true association or residual bias? Am J Gastroenterol. 2022;117(11):1851-7. DOI:10.14309/ajg.0000000000001932
57. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143-50. DOI:10.14336/AD.2017.0306
58. Meyer AM, Ramzan NN, Heigh RI, Leighton JA. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 2006;51(1):168-72. DOI:10.1007/s10620-006-3103-5
59. Long MD, Kappelman MD, Martin CF, et al. Role of nonsteroidal anti-inflammatory drugs in exacerbations of inflammatory bowel disease. J Clin Gastroenterol. 2016;50(2):152-6. DOI:10.1097/MCG.0000000000000421
60. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(2):196-202. DOI:10.1016/s1542-3565(05)00980-8
61. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J. 1981;57(667):297-9. PMID:6117846
62. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: A case-control study. Am J Gastroenterol. 2000;95(8):1949-54. DOI:10.1111/j.1572-0241.2000.02262.x
63. Moninuola OO, Milligan W, Lochhead P, Khalili H. Systematic review with meta-analysis: Association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther. 2018;47(11):1428-39. DOI:10.1111/apt.14606
64. Курсов С.В., Никонов В.В. Циклооксигеназа: физиологические эффекты, действие ингибиторов и перспективы дальнейшего использования парацетамола (аналитический обзор). Медицина неотложных состояний. 2016;5(76):27-35 [Kursov SV, Nikonov VV. Cyclooxygenase: Physilogical effects, inhibitors action and perspectives of paracetamol usage. Emergency Medicine = Medicina neotložnyh sostoânij. 2016;5(76):27-35 (in Russian)]. DOI:10.22141/2224-0586.5.76.2016.76430
65. Miao X, Li J, Ouyang Q, et al. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. Cochrane Database Syst Rev. 2014;2014(10):CD007744. DOI:10.1002/14651858.CD007744.pub2
66. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4(2):203-11. DOI:10.1016/j.cgh.2005.12.002
67. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101(2):311-7. DOI:10.1111/j.1572-0241.2006.00384.x
68. Ribaldone DG, Fagoonee S, Astegiano M, et al. Coxib's safety in patients with inflammatory bowel diseases: A meta-analysis. Pain Physician. 2015;18(6):599-607. PMID: 26606012. Erratum in: Pain Physician. 2016;19(2):101. PMID:26815245
69. Pouillon L, Bossuyt P, Vanderstukken J, et al. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol. 2017;10(12):1363-74. DOI:10.1080/17512433.2017.1377609
70. Ben Nessib D, Ferjani H, Maatallah K, et al. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. Clin Rheumatol. 2020;39(12):3543-53. DOI:10.1007/s10067-020-05136-x
71. D’Haens G. Systematic review: Second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016;44(10):1018-29. DOI:10.1111/apt.13803
72. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19-34. DOI:10.1136/ard-2022-223296
73. Бочкова А.Г. Роль глюкокортикоидов в лечении спондилоартритов. Современная ревматология. 2011;5(1):76-9 [Bochkova AG. Rol' glyukokortikoidovv lechenii spondiloartritov. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2011;5(1):76-9 (in Russian)]. DOI:10.14412/1996-7012-2011-656
74. Dhir V, Mishra D, Samanta J. Glucocorticoids in spondyloarthritis-systematic review and real-world analysis. Rheumatology (Oxford). 2021;60(10):4463-75. DOI:10.1093/rheumatology/keab275
75. Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondyliis. Cochrane Database Syst Rev. 2014;2014(11):CD004800. DOI:10.1002/14651858.CD004800.pub3
76. Chen J, Veras MM, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2013;2013(2):CD004524. DOI:10.1002/14651858.CD004524.pub4
77. Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: A 16-week open-label trial. Ann Rheum Dis. 2007;66(3):419-21. DOI:10.1136/ard.2006.054098
78. Cantini F, Niccoli L, Nannini C, et al. Case-control study on dactylitis, enthesitis, and anterior uveitis in spondyloarthritis associated with inflammatory bowel diseases: role of coexistent psoriasis. J Rheumatol. 2017;44(9):1341-6. DOI:10.3899/jrheum.161518
79. Zu Hoerste MM, Walscheid K, Tappeiner C, et al. The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: Results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol. 2018;256(10):1985-92. DOI:10.1007/s00417-018-4082-x
80. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000;14(Pt. 3A):340-3. DOI:10.1038/eye.2000.84
81. Gordon H, Burisch J, Ellul P, et al. ECCO Guideline on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1-37. DOI:10.1093/ecco-jcc/jjad108
82. Felice C, Pugliese D, Papparella LG, et al. Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert Rev Clin Immunol. 2018;14(9):751-9. DOI:10.1080/1744666X.2018.1513329
83. Barreiro-de-Acosta M, Lorenzo A, Domínguez-Muñoz JE. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn’s disease. Rev Esp Enferm Dig. 2012;104(9):468-72. DOI:10.4321/s1130-01082012000900004
84. Iriarte A, Zaera C, Bachiller-Corral J, López-Sanromán A. Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy. Gastroenterol Hepatol. 2017;40(2):117-21. DOI:10.1016/j.gastrohep.2016.01.011
85. Guillo L, D'Amico F, Danese S, Peyrin-Biroulet L. Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: A systematic literature review. J Crohns Colitis. 2021;15(7):1236-43. DOI:10.1093/ecco-jcc/jjaa260
86. Dubash S, Marianayagam T, Tinazzi I, et al. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology (Oxford). 2019;58(6):963-8. DOI:10.1093/rheumatology/key267
87. Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: A case series. Ann Rheum Dis. 2017;76(5):878-81. DOI:10.1136/annrheumdis-2016-210233
88. Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004-13. DOI:10.1136/annrheumdis-2020-219601
89. Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15(1):25-36.e27. DOI:10.1016/j.cgh.2016.06.025
90. Louis EJ, Reinisch W, Schwartz DA, et al. Adalimumab reduces extraintestinal manifestations in patients with Crohn’s disease: A pooled analysis of 11 clinical studies. Adv Ther. 2018;35(4):563-76. DOI:10.1007/s12325-018-0678-0
91. Vavricka SR, Gubler M, Gantenbein C, et al.; Swiss IBD Cohort Study Group. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study. Inflamm Bowel Dis. 2017;23(7):1174-81. DOI:10.1097/MIB.0000000000001109
92. van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: A double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022;81(11):1515-23. DOI:10.1136/ard-2022-222608
93. Molto A, Sieper J. Peripheral spondyloarthritis: Concept, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2018;32(3):357-68. DOI:10.1016/j.berh.2019.02.010
94. Мазуров В.И., Илюшина Л.В., Долгих С.В., и др. Применение инфликсимаба в лечении анкилозирующего спондилита. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2012;4(3):99-107 [Mazurov VI, Iljushina LV, Dolgikh SV, et al. Infliximab in the treatment of ankylosing spondylitis. Herald of North-Western State Medical University named after I.I. Mechnikov. 2012;4(3):99-107 (in Russian)].
95. Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;2015(4):CD005468. DOI:10.1002/14651858.CD005468.pub2
96. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet. 2002;359(9317):1541-9. DOI:10.1016/S0140-6736(02)08512-4
97. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. DOI:10.1056/NEJMoa050516
98. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805-11. DOI:10.1053/j.gastro.2005.03.003
99. Bieber A, Fawaz A, Novofastovski I, Mader R. Antitumor necrosis factor-α therapy associated with inflammatory bowel disease: Three cases and a systematic literature review. J Rheumatol. 2017;44(7):1088-95. DOI:10.3899/jrheum.160952
100. Gomollón F, Dignass A, Annese V, et al.; ECCO. 3rd European Evidence-based Consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis. 2017;11(1):3-25. DOI:10.1093/ecco-jcc/jjw168
101. Никонов Е.Л., Аксёнов В.А., Скворцова Т.А., Жарова М.Е. Иммунотерапия воспалительных заболеваний кишечника. Доктор.Ру. 2019;10(165):31-7 [Nikonov EL, Aksyonov VA, Skvortsova TA, Zharova ME. Immunotherapy for inflammatory bowel disease. Doctor.Ru. 2019;10(165):31-7 (in Russian)]. DOI:10.31550/1727-2378-2019-165-10-31-37
102. Núñez P, Quera R, Yarur AJ. Safety of Janus kinase inhibitors in inflammatory bowel diseases. Drugs. 2023;83(4):299-314. DOI:10.1007/s40265-023-01840-5
103. Насонов Е.Л. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: перспективы. Терапевтический архив. 2022;94(5):605-9 [Nasonov EL. Janus kinase inhibitors in immunoinflammatory rheumatic diseases. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(5):605-9 (in Russian)]. DOI:10.26442/00403660.2022.05.201501
104. Насонов Е.Л., Коротаева Т.В. Ингибиторы Янус-киназ при иммуновоспалительных заболеваниях: 10 лет клинической практики в ревматологии. Научно-практическая ревматология. 2022;60(2):131-48 [Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Rheumatology Science and Practice. 2022;60(2):131-48 (in Russian)]. DOI:10.47360/1995-4484-2022-131-148
105. Lee YH, Song GG. Janus kinase inhibitors for treating active ankylosing spondylitis: A meta-analysis of randomized controlled trials. Z Rheumatol. 2022;81(1):71-6. DOI:10.1007/s00393-020-00948-3
106. Dobbin-Sears I, Roberts J, O'Rielly DD, Rahman P. Ustekinumab in psoriatic arthritis and related phenotypes. Ther Adv Chronic Dis. 2018;9(10):191-8. DOI:10.1177/2040622318781760
107. Коротаева Т.В., Корсакова Ю.Л., Логинова Е.Ю., и др. Псориатический артрит. Клинические рекомендации по диагностике и лечению. Современная ревматология. 2018;12(2):22-35 [Korotaeva TV, Korsakova YuL, Loginova EYu, et al. Psoriatic arthritis. Clinical guidelines for diagnosis and treatment. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(2):22-35 (in Russian)]. DOI:10.14412/1996-7012-2018-2-22-35
108. Freuer D, Linseisen J, Meisinger C. Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: A bidirectional 2-sample mendelian randomization study. JAMA Dermatol. 2022;158(11):1262-8. DOI:10.1001/jamadermatol.2022.3682
109. Coates LC, Soriano ER, Corp N, et al.; GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. DOI:10.1038/s41584-022-00798-0
110. Feagan BG, Sandborn WJ, Gasink C, et al.; UNITI-IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946-60. DOI:10.1056/NEJMoa1602773
111. Helliwell PS, Gladman DD, Chakravarty SD, et al. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open. 2020;6(1):e001149. DOI:10.1136/rmdopen-2019-001149
112. Новиков П.И., Моисеев С.В. Эффективность и безопасность устекинумаба в лечении псориаза и псориатического артрита. Клиническая фармакология и терапия. 2018;27(5):91-5 [Novikov PI, Moiseev SV. Efficacy and safety of ustekinumab in patients with psoriasis and psoriatic arthritis. Clin Pharmacol Ther. 2018;27(5):91-5 (in Russian)]. DOI:10.32756/0869-5490-2018-5-91-95
113. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-74. DOI:10.1016/S0140-6736(08)60725-4
114. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675-84. DOI:10.1016/S0140-6736(08)60726-6
115. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin-12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633-40. DOI:10.1016/S0140-6736(09)60140-9
116. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990-9. DOI:10.1136/annrheumdis-2013-204655
117. Корсакова Ю.Л., Годзенко А.А., Пчелинцева А.О., и др. Результаты лечения устекинумабом больных псориатическим артритом в Российской Федерации по данным исследований PSUMMIT 1 и PSUMMIT 2. Научно-практическая ревматология. 2015;53(2):125-33 [Korsakova YuL, Godzenko AA, Pchelintseva AO, et al. Results of ustekinumab treatment in patients with psoriatic arthritis in the Russian Federation according to the data of PSUMMIT 1 and PSUMMIT 2. Rheumatology Science and Practice. 2015;53(2):125-33 (in Russian)]. DOI:10.14412/1995-4484-2015-125-133
118. McGonagle D, Watad A, Sharif K, Bridgewood C. Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis. Front Immunol. 2021;12:614255. DOI:10.3389/fimmu.2021.614255
119. Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258-70. DOI:10.1002/art.40728
120. Kawalec P, Holko P, Moćko P, Pilc A. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: A systematic review and network meta-analysis. Rheumatol Int. 2018;38(2):189-201. DOI:10.1007/s00296-017-3919-7
121. Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: What does the evidence say? Am J Clin Dermatol. 2018;19(1):1-13. DOI:10.1007/s40257-017-0328-3
122. No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: A systematic review. J Dermatolog Treat. J Dermatolog Treat. 2018;29(5):460-6. DOI:10.1080/09546634.2017.1398393
123. Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509-19. DOI:10.1111/bjd.16102
124. Campanaro F, Batticciotto A, Zaffaroni A, et al. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmun Rev. 2021;20(10):102902. DOI:10.1016/j.autrev.2021.102902
125. Sarabia S, Ranjith B, Koppikar S, Wijeratne DT. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: A systematic review and meta-analysis. BMC Rheumatol. 2022;6(1):71. DOI:10.1186/s41927-022-00287-7
126. Hueber W, Sands BE, Lewitzky S, et al. Sekukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: Unexpected results of a randomized, double-blind placebo-controlled trial. Gut. 2012;61(12):1692-70. DOI:10.1136/gutjnl-2011-301668
127. Dai С, Huang YH, Jiang M. Combination therapy in inflammatory bowel disease: Current evidence and perspectives. Int Immunopharmacol. 2023:114:109545. DOI:10.1016/j.intimp.2022.109545
128. Triantafillidis JK, Zografos CG, Konstadoulakis MM, Papalois AE. Combination treatment of inflammatory bowel disease: Present status and future perspectives. World J Gastroenterol. 2024;30(15):2068-80. DOI:10.3748/wjg.v30.i15.2068
129. Privitera G, Onali S, Pugliese D, et al. Dual targeted therapy: A possible option for the management of refractory inflammatory bowel disease. J Crohns Colitis. 2020;2020:jjaa149. DOI:10.1093/ecco-jcc/jjaa149
130. Glassner K, Oglat A, Duran A, et al. The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study. J Dig Dis. 2020;21(5):264-71. DOI:10.1111/1751-2980.12867
131. Roblin X, Paul S, Ben-Horin S. Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy. J Crohns Colitis. 2018;12(3):379-80. DOI:10.1093/ecco-jcc/jjx142
132. Miyatani Y, Choi D, Choi NK, Rubin DT. Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn's disease. Dig Dis Sci. 2024;69(2):355-9. DOI:10.1007/s10620-023-08182-y
133. Ribaldone DG, Pellicano R, Vernero M, et al. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: A systematic review with pool analysis. Scand J Gastroenterol. 2019;54(4):407-13. DOI:10.1080/00365521.2019.1597159
134. Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(3):e361-79. DOI:10.1016/j.cgh.2021.03.034
135. Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: Systematic review and meta- analysis. Am J Gastroenterol. 2016;111(5):632-47. DOI:10.1038/ajg.2016.54
136. Mahmoud R, van Lieshout C, Frederix GWJ, et al.; AWARE study group. Continuation of anti-TNF in patients with ulcerative colitis in remission is not cost-effective compared with treatment withdrawal: A Markov model. J Crohns Colitis. 2021;15(5):709-18. DOI:10.1093/ecco-jcc/jjaa219
137. Buer LCT, Høivik ML, Warren DJ et al. Combining antiTNF-α and vedolizumab in the treatment of inflammatory bowel disease: A case series. Inflamm Bowel Dis. 2018;24(5):997-1004. DOI:10.1093/ibd/izx110
138. Парфенов А.И., Каграманова А.В., Князев О.В. Системные проявления воспалительных заболеваний кишечника. Терапевтический архив. 2020;92(2):4-11 [Parfenov AI, Knyazev OV, Kagramanova AV. Systemic manifestations of inflammatory bowel diseases. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):4-11. (in Russian)]. DOI:10.26442/00403660.2020.02.000535

________________________________________________

1. Nasonov EL, Abdulganieva DI, Fairushina IF. The use of Tofacitinib in the treatment of inflammatory bowel disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(2):101-8 (in Russian). DOI:10.26442/00403660.2019.02.000155
2. Harbord M, Annese V, Vavricka SR, et al.; European Crohn’s and Colitis Organisation. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239-54. DOI:10.1093/ecco-jcc/jjv213
3. Hedin CRH, Vavricka SR, Stagg AJ, et al. The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis. 2019;13(5):541-54. DOI:10.1093/ecco-jcc/jjy191
4. Gutiérrez Casbas A, Rodríguez-Lago I, Marín-Jiménez I, et al.; EISER Study Group. DOP60 Prevalence of undiagnosed inflammatory Bowel Disease in patients with spondyloarthritis: EISER Study. J Crohn's and Colitis. 2024;18(Suppl. 1):i182-4. DOI:10.1093/ecco-jcc/jjad212.0100
5. Atzeni F, Defendenti C, Ditto MC, et al. Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):20-3. DOI:10.1016/j.autrev.2013.06.006
6. Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Rheumatology Science and Practice. 2015;53(6):657-60 (in Russian). DOI:10.14412/1995-4484-2015-657-660
7. Erdes ShF. Spondyloarthritis: Evolution of a concept. Rheumatology Science and Practice. 2014;52(5):574-6 (in Russian). DOI:10.14412/1995-4484-2014-574-576
8. Erdes ShF, Rebrov AP, Dubinina TV, et al. Spondyloarthritis: Modern terminology and definitions. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(5):84-8 (in Russian). DOI:10.26442/00403660.2019.05.000208
9. Erdes ShF. Ankiloziruiushchii spondilit. V kn.: Rossiiskie klinicheskie rekomendatsii. Revmatologiia. Pod red. EL Nasonova. Moscow: GEOTAR-Media, 2020 (in Russian).
10. Poddubnyy D, van Tubergen A, Landewé R, et al.; Assessment of SpondyloArthritis international Society (ASAS). Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Ann Rheum Dis. 2015;74(8):1483-7. DOI:10.1136/annrheumdis-2014-207151
11. Godzenko AA. Differentsial'naia diagnostika sustavnogo sindroma. V kn.: Revmatologiia. Klinicheskie lektsii. Pod red. VV Badokina. Moscow: Littera, 2014 (in Russian).
12. Korotaev TV, Korsakova YuL. Psoriatic arthritis: Classification, clinical presentation, diagnosis, treatment. Rheumatology Science and Practice. 2018;56(1):60-9 (in Russian). DOI:10.14412/1995-4484-2018-60-69
13. Rudwaleit M, Jurik A, Hermann K, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: A consensual approach by the ASAS/OMERACT MRI Group. Ann Rheum Dis. 2009;68(10):1520-7. DOI:10.1136/ard.2009.110767
14. Lambert R, Bakker P, van der Heijde D, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: Update by the ASAS MRI Working Group. Ann Rheum Dis. 2016;75(11):1958-63. DOI:10.1136/annrheumdis-2015-208642
15. Bochkova AG, Levshakova AV. Kratkoe metodicheskoe rukovodstvo po obsledovaniiu bol'nykh spondiloartritami. Moscow. 2012 (in Russian).
16. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65-73. DOI:10.1136/annrheumdis-2013-203582
17. Maev IV, Bakulin IG, Skalinskaya MI, Skazyvaeva EV. Inflammatory bowel diseases: Transformation of representations. A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(12):1064-74 (in Russian). DOI:10.26442/00403660.2023.12.202507
18. Linstone H, Turoff M. The Delphi method: Techniques and applications. Available at: https://web.archive.org/web/20080520015240/http:/is.njit.edu/pubs/delphibook/ Accessed: 22.01.2024.
19. Tavassoli S, Shahabinasab I, Norouzi A, et al. From bowel inflammation to the bone and joints: Musculoskeletal examination in inflammatory bowel disease (IBD). BMC Musculoskelet Disord. 2021;22(1):1019. DOI:10.1186/s12891-021-04903-4
20. Nikitin AV, Volynets GV, Skvortsova TA, Kapranova MS. Extraintestinal manifestations of inflammatory bowel disease. Russian Journal of Evidence-Based Gastroenterology. 2023;12(1):93-8 (in Russian). DOI:10.17116/dokgastro20231201193
21. Kuzin AV. Injury to the joint and spinal column in patients with inflammatory bowel diseases. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(2):78-82 (in Russian). DOI:10.14412/1996-7012-2016-2-78-82
22. Bakulin IG, Skalinskaya MI, Skazyvaeva EV, et al. Extraintestinal manifestations of inflammatory bowel diseases: Modern conception and contribution to the disease insight. Therapy. 2022;8(1):71-93 (in Russian). DOI:10.18565/therapy.2022.1.71-93
23. Erdes ShPh, Dubinina TV, Lapshina SА, et al. Modern principles of medical treatment of ankylosing spondylitis. Practical Medicine. 2015;4-2(89):181-9 (in Russian).
24. Erdes ShF. The basic principles of treatment of ankylosing spondylitis (Bechterew's disease). Rheumatology Science and Practice. 2013;51(6):686-95 (in Russian). DOI:10.14412/1995-4484-2013-686-95
25. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. DOI:10.1136/annrheumdis-2016-210770
26. Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73(8):1455-61. DOI:10.1136/annrheumdis-2014-205178
27. Poddubnyy D, Protopopov M, Haibel H, et al. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: Results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis. 2016;75(12):2114-8. DOI:10.1136/annrheumdis-2016-209209
28. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65(4):442-52. DOI:10.1136/ard.2005.041137
29. Braun J, van den Berg R, Baraliakos X. Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896-904. DOI:10.1136/ard.2011.151027
30. Abdulganieva DI, Bakulev AL, Belousova EA, et al. Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2018;12(3):4-18 (in Russian). DOI:10.14412/1996-7012-2018-3-4-18
31. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets Inflammatory Bowel Disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324-38. DOI:10.1038/ajg.2015.23358
32. Тurner D, Ricciuto A, Lewis A, et al.; International Organization for the Study of IBD. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83. DOI:10.1053/j.gastro.2020.12.031
33. Shelygin YuA, Ivashkin VT, Achkasov SI, et al. Clinical guidelines. Crohn’s disease (К50), adults. Koloproktologia. 2023;22(3):10-49 (in Russian). DOI:10.33878/2073-7556-2023-22-3-10-49
34. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000;118(2):274-8. DOI:10.1016/s0016-5085(00)70209-5
35. Palm Ø, Moum B, Jahnsen J, Gran JT. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatol (Oxford). 2001;40(11):1256-61. DOI:10.1093/rheumatology/40.11.1256
36. Yüksel I, Ataseven H, Başar O, et al. Peripheral arthritis in the course of inflammatory bowel diseases. Dig Dis Sci. 2011;56(1):183-7. DOI:10.1007/s10620-010-1260-z
37. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol. 1988;83(7):703-9. PMID:3289378
38. Greenstein A, Janowitz H, Sachar D. Extra-intestinal complications of Crohn’s disease and ulcerative colitis. Medicine (Baltimore). 1976;55(5):401-12. DOI:10.1097/00005792-197609000-00004
39. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis. 2009;68(6):777-83. DOI:10.1136/ard.2009.108233
40. Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25-31. DOI:10.1136/ard.2010.133645
41. Salvarani C, Vlachonikolis IG, van der Heijde DM, et al.; European Collaborative IBD Study Group. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36(12):1307-13. DOI:10.1080/003655201317097173
42. Chen Y, Chen L, Xing C, et al. The risk of rheumatoid arthritis among patients with inflammatory bowel disease: A systematic review and meta-analysis. BMC Gastroenterol. 2020;20(1):192. DOI:10.1186/s12876-020-01339-3
43. Kärnsund S, Lo B, Bendtsen F, et al. Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J Gastroenterol. 2020;26(35):5362-74. DOI:10.3748/wjg.v26.i35.5362
44. Hidalgo DF, Boonpheng B, Phemister J, et al. Inflammatory bowel disease and risk of osteoporotic fractures: A meta-analysis. Cureus. 2019;11(9):e5810. DOI:10.7759/cureus.5810
45. Lo B, Holm JP, Vester-Andersen MK, et al. Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease: A Danish population-based inception cohort with 10 years of follow-up. J Crohns Colitis. 2020;14(7):904-14. DOI:10.1093/ecco-jcc/jjaa019
46. Komaki Y, Komaki F, Micic D, et al. Risk of fractures in inflammatory bowel diseases: A systematic review and meta-analysis. J Clin Gastroenterol. 2019;53(6):441-8. DOI:10.1097/MCG.0000000000001031
47. Szafors P, Che H, Barnetche T, et al. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int. 2018;29(11):2389-97. DOI:10.1007/s00198-018-4586-6
48. Shelygin YuA, Ivashkin VT, Belousova EA, Ulcerative colitis (K51), adults. Clinical Guidelines. Koloproktologia. 2023;22(1):10-44 (in Russian). DOI:10.33878/2073-7556-2023-22-1-10-44
49. Dubinina TV, Gaidukova IZ, Godzenko AA, et al. Guidelines for the assessment of disease activity and functional status in patients with ankylosing spondylitis in clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):344-50 (in Russian). DOI:10.14412/1995-4484-2017-344-350
50. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl. 2):ii1-44. DOI:10.1136/ard.2008.104018
51. Van der Heijde D, Lie E, Kvien TK, et al.; Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811-8. DOI:10.1136/ard.2008.100826
52. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285-99. DOI:10.1002/acr.24025
53. Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20939410. DOI:10.1177/1759720X20939410
54. Wallace JL. Prostaglandin biology in inflammatory bowel disease. Gastroenterol Clin North Am. 2001;30(4):971-80. DOI:10.1016/s0889-8553(05)70223-5
55. Gaidukova IZ, Rebrov AP, Otteva EN, et al. Use of nonsteroidal anti-inflammatory drugs for the treatment of axial spondyloarthritis, including ankylosing spondylitis, monitoring their efficacy and safety (draft guidelines of the Expert Spondyloarthritis Diagnosis and Treatment Group). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl. 1):67-74 (in Russian). DOI:10.14412/1995-4484-2016-1S-67-74
56. Cohen-Mekelburg S, Van T, Wallace B, et al. The association between nonsteroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: A true association or residual bias? Am J Gastroenterol. 2022;117(11):1851-7. DOI:10.14309/ajg.0000000000001932
57. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143-50. DOI:10.14336/AD.2017.0306
58. Meyer AM, Ramzan NN, Heigh RI, Leighton JA. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 2006;51(1):168-72. DOI:10.1007/s10620-006-3103-5
59. Long MD, Kappelman MD, Martin CF, et al. Role of nonsteroidal anti-inflammatory drugs in exacerbations of inflammatory bowel disease. J Clin Gastroenterol. 2016;50(2):152-6. DOI:10.1097/MCG.0000000000000421
60. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(2):196-202. DOI:10.1016/s1542-3565(05)00980-8
61. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J. 1981;57(667):297-9. PMID:6117846
62. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: A case-control study. Am J Gastroenterol. 2000;95(8):1949-54. DOI:10.1111/j.1572-0241.2000.02262.x
63. Moninuola OO, Milligan W, Lochhead P, Khalili H. Systematic review with meta-analysis: Association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther. 2018;47(11):1428-39. DOI:10.1111/apt.14606
64. Kursov SV, Nikonov VV. Cyclooxygenase: Physilogical effects, inhibitors action and perspectives of paracetamol usage. Emergency Medicine = Medicina neotložnyh sostoânij. 2016;5(76):27-35 (in Russian). DOI:10.22141/2224-0586.5.76.2016.76430
65. Miao X, Li J, Ouyang Q, et al. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. Cochrane Database Syst Rev. 2014;2014(10):CD007744. DOI:10.1002/14651858.CD007744.pub2
66. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4(2):203-11. DOI:10.1016/j.cgh.2005.12.002
67. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101(2):311-7. DOI:10.1111/j.1572-0241.2006.00384.x
68. Ribaldone DG, Fagoonee S, Astegiano M, et al. Coxib's safety in patients with inflammatory bowel diseases: A meta-analysis. Pain Physician. 2015;18(6):599-607. PMID: 26606012. Erratum in: Pain Physician. 2016;19(2):101. PMID:26815245
69. Pouillon L, Bossuyt P, Vanderstukken J, et al. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol. 2017;10(12):1363-74. DOI:10.1080/17512433.2017.1377609
70. Ben Nessib D, Ferjani H, Maatallah K, et al. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. Clin Rheumatol. 2020;39(12):3543-53. DOI:10.1007/s10067-020-05136-x
71. D’Haens G. Systematic review: Second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016;44(10):1018-29. DOI:10.1111/apt.13803
72. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19-34. DOI:10.1136/ard-2022-223296
73. Bochkova AG. Rol' glyukokortikoidovv lechenii spondiloartritov. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2011;5(1):76-9 (in Russian). DOI:10.14412/1996-7012-2011-656
74. Dhir V, Mishra D, Samanta J. Glucocorticoids in spondyloarthritis-systematic review and real-world analysis. Rheumatology (Oxford). 2021;60(10):4463-75. DOI:10.1093/rheumatology/keab275
75. Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondyliis. Cochrane Database Syst Rev. 2014;2014(11):CD004800. DOI:10.1002/14651858.CD004800.pub3
76. Chen J, Veras MM, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2013;2013(2):CD004524. DOI:10.1002/14651858.CD004524.pub4
77. Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: A 16-week open-label trial. Ann Rheum Dis. 2007;66(3):419-21. DOI:10.1136/ard.2006.054098
78. Cantini F, Niccoli L, Nannini C, et al. Case-control study on dactylitis, enthesitis, and anterior uveitis in spondyloarthritis associated with inflammatory bowel diseases: role of coexistent psoriasis. J Rheumatol. 2017;44(9):1341-6. DOI:10.3899/jrheum.161518
79. Zu Hoerste MM, Walscheid K, Tappeiner C, et al. The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: Results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol. 2018;256(10):1985-92. DOI:10.1007/s00417-018-4082-x
80. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000;14(Pt. 3A):340-3. DOI:10.1038/eye.2000.84
81. Gordon H, Burisch J, Ellul P, et al. ECCO Guideline on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1-37. DOI:10.1093/ecco-jcc/jjad108
82. Felice C, Pugliese D, Papparella LG, et al. Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert Rev Clin Immunol. 2018;14(9):751-9. DOI:10.1080/1744666X.2018.1513329
83. Barreiro-de-Acosta M, Lorenzo A, Domínguez-Muñoz JE. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn’s disease. Rev Esp Enferm Dig. 2012;104(9):468-72. DOI:10.4321/s1130-01082012000900004
84. Iriarte A, Zaera C, Bachiller-Corral J, López-Sanromán A. Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy. Gastroenterol Hepatol. 2017;40(2):117-21. DOI:10.1016/j.gastrohep.2016.01.011
85. Guillo L, D'Amico F, Danese S, Peyrin-Biroulet L. Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: A systematic literature review. J Crohns Colitis. 2021;15(7):1236-43. DOI:10.1093/ecco-jcc/jjaa260
86. Dubash S, Marianayagam T, Tinazzi I, et al. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology (Oxford). 2019;58(6):963-8. DOI:10.1093/rheumatology/key267
87. Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: A case series. Ann Rheum Dis. 2017;76(5):878-81. DOI:10.1136/annrheumdis-2016-210233
88. Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004-13. DOI:10.1136/annrheumdis-2020-219601
89. Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15(1):25-36.e27. DOI:10.1016/j.cgh.2016.06.025
90. Louis EJ, Reinisch W, Schwartz DA, et al. Adalimumab reduces extraintestinal manifestations in patients with Crohn’s disease: A pooled analysis of 11 clinical studies. Adv Ther. 2018;35(4):563-76. DOI:10.1007/s12325-018-0678-0
91. Vavricka SR, Gubler M, Gantenbein C, et al.; Swiss IBD Cohort Study Group. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study. Inflamm Bowel Dis. 2017;23(7):1174-81. DOI:10.1097/MIB.0000000000001109
92. van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: A double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022;81(11):1515-23. DOI:10.1136/ard-2022-222608
93. Molto A, Sieper J. Peripheral spondyloarthritis: Concept, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2018;32(3):357-68. DOI:10.1016/j.berh.2019.02.010
94. Mazurov VI, Iljushina LV, Dolgikh SV, et al. Infliximab in the treatment of ankylosing spondylitis. Herald of North-Western State Medical University named after I.I. Mechnikov. 2012;4(3):99-107 (in Russian).
95. Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;2015(4):CD005468. DOI:10.1002/14651858.CD005468.pub2
96. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet. 2002;359(9317):1541-9. DOI:10.1016/S0140-6736(02)08512-4
97. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. DOI:10.1056/NEJMoa050516
98. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805-11. DOI:10.1053/j.gastro.2005.03.003
99. Bieber A, Fawaz A, Novofastovski I, Mader R. Antitumor necrosis factor-α therapy associated with inflammatory bowel disease: Three cases and a systematic literature review. J Rheumatol. 2017;44(7):1088-95. DOI:10.3899/jrheum.160952
100. Gomollón F, Dignass A, Annese V, et al.; ECCO. 3rd European Evidence-based Consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis. 2017;11(1):3-25. DOI:10.1093/ecco-jcc/jjw168
101. Nikonov EL, Aksyonov VA, Skvortsova TA, Zharova ME. Immunotherapy for inflammatory bowel disease. Doctor.Ru. 2019;10(165):31-7 (in Russian). DOI:10.31550/1727-2378-2019-165-10-31-37
102. Núñez P, Quera R, Yarur AJ. Safety of Janus kinase inhibitors in inflammatory bowel diseases. Drugs. 2023;83(4):299-314. DOI:10.1007/s40265-023-01840-5
103. Nasonov EL. Janus kinase inhibitors in immunoinflammatory rheumatic diseases. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(5):605-9 (in Russian). DOI:10.26442/00403660.2022.05.201501
104. Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Rheumatology Science and Practice. 2022;60(2):131-48 (in Russian). DOI:10.47360/1995-4484-2022-131-148
105. Lee YH, Song GG. Janus kinase inhibitors for treating active ankylosing spondylitis: A meta-analysis of randomized controlled trials. Z Rheumatol. 2022;81(1):71-6. DOI:10.1007/s00393-020-00948-3
106. Dobbin-Sears I, Roberts J, O'Rielly DD, Rahman P. Ustekinumab in psoriatic arthritis and related phenotypes. Ther Adv Chronic Dis. 2018;9(10):191-8. DOI:10.1177/2040622318781760
107. Korotaeva TV, Korsakova YuL, Loginova EYu, et al. Psoriatic arthritis. Clinical guidelines for diagnosis and treatment. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(2):22-35 (in Russian). DOI:10.14412/1996-7012-2018-2-22-35
108. Freuer D, Linseisen J, Meisinger C. Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: A bidirectional 2-sample mendelian randomization study. JAMA Dermatol. 2022;158(11):1262-8. DOI:10.1001/jamadermatol.2022.3682
109. Coates LC, Soriano ER, Corp N, et al.; GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. DOI:10.1038/s41584-022-00798-0
110. Feagan BG, Sandborn WJ, Gasink C, et al.; UNITI-IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946-60. DOI:10.1056/NEJMoa1602773
111. Helliwell PS, Gladman DD, Chakravarty SD, et al. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open. 2020;6(1):e001149. DOI:10.1136/rmdopen-2019-001149
112. Novikov PI, Moiseev SV. Efficacy and safety of ustekinumab in patients with psoriasis and psoriatic arthritis. Clin Pharmacol Ther. 2018;27(5):91-5 (in Russian). DOI:10.32756/0869-5490-2018-5-91-95
113. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-74. DOI:10.1016/S0140-6736(08)60725-4
114. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675-84. DOI:10.1016/S0140-6736(08)60726-6
115. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin-12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633-40. DOI:10.1016/S0140-6736(09)60140-9
116. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990-9. DOI:10.1136/annrheumdis-2013-204655
117. Korsakova YuL, Godzenko AA, Pchelintseva AO, et al. Results of ustekinumab treatment in patients with psoriatic arthritis in the Russian Federation according to the data of PSUMMIT 1 and PSUMMIT 2. Rheumatology Science and Practice. 2015;53(2):125-33 (in Russian). DOI:10.14412/1995-4484-2015-125-133
118. McGonagle D, Watad A, Sharif K, Bridgewood C. Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis. Front Immunol. 2021;12:614255. DOI:10.3389/fimmu.2021.614255
119. Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258-70. DOI:10.1002/art.40728
120. Kawalec P, Holko P, Moćko P, Pilc A. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: A systematic review and network meta-analysis. Rheumatol Int. 2018;38(2):189-201. DOI:10.1007/s00296-017-3919-7
121. Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: What does the evidence say? Am J Clin Dermatol. 2018;19(1):1-13. DOI:10.1007/s40257-017-0328-3
122. No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: A systematic review. J Dermatolog Treat. J Dermatolog Treat. 2018;29(5):460-6. DOI:10.1080/09546634.2017.1398393
123. Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509-19. DOI:10.1111/bjd.16102
124. Campanaro F, Batticciotto A, Zaffaroni A, et al. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmun Rev. 2021;20(10):102902. DOI:10.1016/j.autrev.2021.102902
125. Sarabia S, Ranjith B, Koppikar S, Wijeratne DT. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: A systematic review and meta-analysis. BMC Rheumatol. 2022;6(1):71. DOI:10.1186/s41927-022-00287-7
126. Hueber W, Sands BE, Lewitzky S, et al. Sekukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: Unexpected results of a randomized, double-blind placebo-controlled trial. Gut. 2012;61(12):1692-70. DOI:10.1136/gutjnl-2011-301668
127. Dai С, Huang YH, Jiang M. Combination therapy in inflammatory bowel disease: Current evidence and perspectives. Int Immunopharmacol. 2023:114:109545. DOI:10.1016/j.intimp.2022.109545
128. Triantafillidis JK, Zografos CG, Konstadoulakis MM, Papalois AE. Combination treatment of inflammatory bowel disease: Present status and future perspectives. World J Gastroenterol. 2024;30(15):2068-80. DOI:10.3748/wjg.v30.i15.2068
129. Privitera G, Onali S, Pugliese D, et al. Dual targeted therapy: A possible option for the management of refractory inflammatory bowel disease. J Crohns Colitis. 2020;2020:jjaa149. DOI:10.1093/ecco-jcc/jjaa149
130. Glassner K, Oglat A, Duran A, et al. The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study. J Dig Dis. 2020;21(5):264-71. DOI:10.1111/1751-2980.12867
131. Roblin X, Paul S, Ben-Horin S. Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy. J Crohns Colitis. 2018;12(3):379-80. DOI:10.1093/ecco-jcc/jjx142
132. Miyatani Y, Choi D, Choi NK, Rubin DT. Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn's disease. Dig Dis Sci. 2024;69(2):355-9. DOI:10.1007/s10620-023-08182-y
133. Ribaldone DG, Pellicano R, Vernero M, et al. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: A systematic review with pool analysis. Scand J Gastroenterol. 2019;54(4):407-13. DOI:10.1080/00365521.2019.1597159
134. Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(3):e361-79. DOI:10.1016/j.cgh.2021.03.034
135. Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: Systematic review and meta- analysis. Am J Gastroenterol. 2016;111(5):632-47. DOI:10.1038/ajg.2016.54
136. Mahmoud R, van Lieshout C, Frederix GWJ, et al.; AWARE study group. Continuation of anti-TNF in patients with ulcerative colitis in remission is not cost-effective compared with treatment withdrawal: A Markov model. J Crohns Colitis. 2021;15(5):709-18. DOI:10.1093/ecco-jcc/jjaa219
137. Buer LCT, Høivik ML, Warren DJ et al. Combining antiTNF-α and vedolizumab in the treatment of inflammatory bowel disease: A case series. Inflamm Bowel Dis. 2018;24(5):997-1004. DOI:10.1093/ibd/izx110
138. Parfenov AI, Knyazev OV, Kagramanova AV. Systemic manifestations of inflammatory bowel diseases. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):4-11. (in Russian). DOI:10.26442/00403660.2020.02.000535

Авторы

Г.В. Лукина^1,2, О.В. Князев*¹, Е.А. Белоусова³, Д.И. Абдулганиева⁴, Е.Н. Александрова¹, И.Г. Бакулин⁵, О.Ю. Барышева⁶, М.А. Борисова¹, Б.А. Выкова⁷, А.А. Годзенко⁸, И.В. Губонина⁹, Т.В. Дубинина², Т.Н. Жигалова¹⁰, Е.В. Жиляев^8,11,12, А.В. Каграманова¹, Т.В. Коротаева², А.В. Кузин⁸, М.А. Ливзан¹³, А.М. Лила², В.И. Мазуров¹⁴, Е.Л. Насонов², А.А. Новиков^1,12, М.Ф. Осипенко¹⁵, А.И. Парфенов¹, Л.В. Тарасова^16,17, О.В. Хлынова¹⁸, М.В. Шапина⁷, О.Б. Щукина¹⁹, Ш.Ф. Эрдес², А.А. Яковлев²⁰

¹ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия;
²ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
³ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского», Москва, Россия;
⁴Министерство здравоохранения Республики Татарстан, Казань, Россия;
⁵ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, Санкт-Петербург, Россия;
⁶ГБУЗ РК «Республиканская больница им. В.А. Баранова», Петрозаводск, Россия;
⁷ФГБУ «Национальный медицинский исследовательский центр колопроктологии им. А.Н. Рыжих» Минздрава России, Москва, Россия;
⁸ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
⁹Многопрофильная клиника «Скандинавия» (ООО «АВА-ПЕТЕР»), Санкт-Петербург, Россия;
¹⁰ГУЗ «Городская клиническая больница №31», Санкт-Петербург, Россия;
¹¹АО «Европейский медицинский центр», Москва, Россия;
¹²ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России (Пироговский Университет), Москва, Россия;
¹³ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия;
¹⁴ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, Санкт-Петербург, Россия;
¹⁵ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России, Новосибирск, Россия;
¹⁶ФГБОУ ВО «Чувашский государственный университет им. И.Н. Ульянова», Чебоксары, Россия;
¹⁷БУ ЧР «Республиканская клиническая больница» Минздрава Чувашской Республики, Чебоксары, Россия;
¹⁸ФГБОУ ВО «Пермский государственный медицинский университет им. акад. Е.А. Вагнера» Минздрава России, Пермь, Россия;
¹⁹ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия;
²⁰ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России, Ростов-на-Дону, Россия
*oleg7@bk.ru

________________________________________________

Galina V. Lukina^1,2, Oleg V. Knyazev*¹, Elena A. Belousova³, Diana I. Abdulganieva⁴, Elena N. Aleksandrova¹, Igor G. Bakulin⁵, Olga Iu. Barysheva⁶, Maria А. Borisova¹, Bella А. Vykova⁷, Alla А. Godzenko⁸, Irina V. Gubonina⁹, Tatiana V. Dubinina², Tatiana N. Zhigalova¹⁰, Evgeny V. Zhilyaev^8,11,12, Anna V. Kagramanova¹, Tatiana V. Korotaeva², Alexander V. Kuzin⁸, Maria A. Livzan¹³, Aleksander M. Lila², Vadim I. Mazurov¹⁴, Evgeny L. Nasonov², Alexander A. Novikov^1,12, Marina F. Osipenko¹⁵, Asfold I. Parfenov¹, Larisa V. Tarasova^16,17, Olga V. Khlynova¹⁸, Marina V. Shapina⁷, Oksana B. Shchukina¹⁹, Shandor F. Erdes², Aleksei A. Iakovlev²⁰

¹Loginov Moscow Clinical Scientific Center, Moscow, Russia;
²Nasonova Research Institute of Rheumatology, Moscow, Russia;
³Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia;
⁴Ministry of Health of the Republic of Tatarstan, Kazan, Russia;
⁵Mechnikov North-Western State Medical University, Saint Petersburg, Russia;
⁶Baranov Republican Hospital, Petrozavodsk, Russia;
⁷Ryzikh National Medical Research Centre for Coloproctology, Moscow, Russia;
⁸Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
⁹Scandinavia Multidisciplinary Clinic (AVA-PETER LLC), Saint Petersburg, Russia;
¹⁰City Clinical Hospital No. 31, Saint Petersburg, Russia;
¹¹European Medical Center JSC, Moscow, Russia;
¹²Pirogov Russian National Research Medical University (Pirogov University), Moscow, Russia;
¹³Omsk State Medical University, Omsk, Russia;
¹⁴Mechnikov North-Western State Medical University, Saint Petersburg, Russia;
¹⁵Novosibirsk State Medical University, Novosibirsk, Russia;
¹⁶Ulyanov Chuvash State University, Cheboksary, Russia;
¹⁷Republican Clinical Hospital, Cheboksary, Russia;
¹⁸Academician Vagner Perm State Medical University, Perm, Russia;
¹⁹Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
²⁰Rostov State Medical University, Rostov-on-Don, Russia
*oleg7@bk.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.